Full-Length Original Research
A comprehensive behavioral evaluation in the lithium–pilocarpine model in rats: Effects of carisbamate administration during status epilepticus
Article first published online: 11 MAY 2013
Wiley Periodicals, Inc. © 2013 International League Against Epilepsy
Volume 54, Issue 7, pages 1203–1213, July 2013
How to Cite
Faure, J.-B., Akimana, G., Carneiro, J. E. M., Cosquer, B., Ferrandon, A., Geiger, K., Koning, E., Penazzi, L., Cassel, J.-C. and Nehlig, A. (2013), A comprehensive behavioral evaluation in the lithium–pilocarpine model in rats: Effects of carisbamate administration during status epilepticus. Epilepsia, 54: 1203–1213. doi: 10.1111/epi.12219
- Issue published online: 1 JUL 2013
- Article first published online: 11 MAY 2013
- Manuscript Accepted: 8 APR 2013
- French Ministry of Research
- French Institut National de la Science et de la Recherche Médicale. Grant Number: INSERM U 666
- French Centre National de la Recherche Scienfifique. Grant Number: CNRS-UDS UMR 7237
- Temporal lobe epilepsy;
- Learning and memory
Administration of carisbamate during status epilepticus (SE) prevents the occurrence of motor seizures in the lithium–pilocarpine model and leads in a subpopulation of rats to spike-and-wave discharges characteristic of absence epilepsy. Widespread neuroprotection accompanied this change in seizure expression. To assess whether these carisbamate-induced changes affected comorbidity, we used a large battery of behavioral tests in rats that had developed temporal lobe or absence-like seizures.
Lithium–pilocarpine or saline was administered to 60 adult rats. Carisbamate (90 mg/kg) or diazepam and saline was given 1 h after SE onset, and repeated 8 h later and twice daily over 6 more days. Rats were video-monitored for 2 months. Subsequently, locomotor activity, anxiety, and various types of memory were assessed.
In rats with motor seizures, treated or not with carisbamate, all features of behavior were impaired compared to controls. Rats exhibiting absence-like seizures after carisbamate treatment behaved as controls in all paradigms tested along with widespread neuroprotection.
Carisbamate treatment leading to absence-like instead of temporal lobe seizures impressively prevented behavioral comorbidities reported by patients with epilepsy as the most disabling.